Clinical data | |
---|---|
Trade names | Leukeran, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682899 |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | Liver |
Elimination half-life | 1.5 hours |
Excretion | N/A |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.005.603 |
Chemical and physical data | |
Formula | C14H19Cl2NO2 |
Molar mass | 304.21 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma.[2] For CLL it is a preferred treatment.[3] It is given by mouth.[3]
Common side effects include bone marrow suppression.[3] Other serious side effects include an increased long term risk of further cancer, infertility, and allergic reactions.[3] Use during pregnancy often results in harm to the baby.[3] Chlorambucil is in the alkylating agent family of medications.[3] It works by blocking the formation of DNA and RNA.[3]
Chlorambucil was approved for medical use in the United States in 1957.[3] It is on the World Health Organization's List of Essential Medicines.[4][5] It was originally made from nitrogen mustard.[3]